Localisation of mesenchymal tumours by somatostatin receptor imaging

Suzanne M Jan De Beur, Elizabeth A. Streeten, Ali Civelek, Edward F McCarthy, Liliana Uribe, Stephen J. Marx, Olufunmilayo Onobrakpeya, Lawrence G. Raisz, Nelson B. Watts, Michael Sharon, Michael A. Levine

Research output: Contribution to journalArticle

Abstract

Oncogenic osteomalacia, an acquired hypophosphataemic syndrome associated with mesenchymal tumours, is characterised by hypophosphataemia secondary to inappropriate phosphaturia, reduced concentrations of serum calcitriol, and defective bone mineralisation. Removal of these tumours results in complete reversal of these biochemical defects. However, because these tumours are small, slow-growing, and frequently situated in unusual anatomical sites, conventional imaging techniques often fail to detect them. Since mesenchymal tumours express somatostatin receptors, we postulated that somatostatin analogues would be able to detect these tumours. We did Indium-111 labeled pentetreotide imaging in seven patients with oncogenic osteomalacia. In five patients, we identified a mesenchymal tumour, and clinical improvement occurred after tumour resection. Our findings suggest that 111In-pentetreotide imaging effectively detects occult mesenchymal tumours and facilitates surgical treatment of oncogenic osteomalacia.

Original languageEnglish (US)
Pages (from-to)761-763
Number of pages3
JournalThe Lancet
Volume359
Issue number9308
DOIs
StatePublished - Mar 2 2002

Fingerprint

Somatostatin Receptors
Neoplasms
Familial Hypophosphatemia
Physiologic Calcification
Calcitriol
Somatostatin
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jan De Beur, S. M., Streeten, E. A., Civelek, A., McCarthy, E. F., Uribe, L., Marx, S. J., ... Levine, M. A. (2002). Localisation of mesenchymal tumours by somatostatin receptor imaging. The Lancet, 359(9308), 761-763. https://doi.org/10.1016/S0140-6736(02)07846-7

Localisation of mesenchymal tumours by somatostatin receptor imaging. / Jan De Beur, Suzanne M; Streeten, Elizabeth A.; Civelek, Ali; McCarthy, Edward F; Uribe, Liliana; Marx, Stephen J.; Onobrakpeya, Olufunmilayo; Raisz, Lawrence G.; Watts, Nelson B.; Sharon, Michael; Levine, Michael A.

In: The Lancet, Vol. 359, No. 9308, 02.03.2002, p. 761-763.

Research output: Contribution to journalArticle

Jan De Beur, SM, Streeten, EA, Civelek, A, McCarthy, EF, Uribe, L, Marx, SJ, Onobrakpeya, O, Raisz, LG, Watts, NB, Sharon, M & Levine, MA 2002, 'Localisation of mesenchymal tumours by somatostatin receptor imaging', The Lancet, vol. 359, no. 9308, pp. 761-763. https://doi.org/10.1016/S0140-6736(02)07846-7
Jan De Beur, Suzanne M ; Streeten, Elizabeth A. ; Civelek, Ali ; McCarthy, Edward F ; Uribe, Liliana ; Marx, Stephen J. ; Onobrakpeya, Olufunmilayo ; Raisz, Lawrence G. ; Watts, Nelson B. ; Sharon, Michael ; Levine, Michael A. / Localisation of mesenchymal tumours by somatostatin receptor imaging. In: The Lancet. 2002 ; Vol. 359, No. 9308. pp. 761-763.
@article{f9030cbe71af4a28a16439c9ce8e3cc9,
title = "Localisation of mesenchymal tumours by somatostatin receptor imaging",
abstract = "Oncogenic osteomalacia, an acquired hypophosphataemic syndrome associated with mesenchymal tumours, is characterised by hypophosphataemia secondary to inappropriate phosphaturia, reduced concentrations of serum calcitriol, and defective bone mineralisation. Removal of these tumours results in complete reversal of these biochemical defects. However, because these tumours are small, slow-growing, and frequently situated in unusual anatomical sites, conventional imaging techniques often fail to detect them. Since mesenchymal tumours express somatostatin receptors, we postulated that somatostatin analogues would be able to detect these tumours. We did Indium-111 labeled pentetreotide imaging in seven patients with oncogenic osteomalacia. In five patients, we identified a mesenchymal tumour, and clinical improvement occurred after tumour resection. Our findings suggest that 111In-pentetreotide imaging effectively detects occult mesenchymal tumours and facilitates surgical treatment of oncogenic osteomalacia.",
author = "{Jan De Beur}, {Suzanne M} and Streeten, {Elizabeth A.} and Ali Civelek and McCarthy, {Edward F} and Liliana Uribe and Marx, {Stephen J.} and Olufunmilayo Onobrakpeya and Raisz, {Lawrence G.} and Watts, {Nelson B.} and Michael Sharon and Levine, {Michael A.}",
year = "2002",
month = "3",
day = "2",
doi = "10.1016/S0140-6736(02)07846-7",
language = "English (US)",
volume = "359",
pages = "761--763",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9308",

}

TY - JOUR

T1 - Localisation of mesenchymal tumours by somatostatin receptor imaging

AU - Jan De Beur, Suzanne M

AU - Streeten, Elizabeth A.

AU - Civelek, Ali

AU - McCarthy, Edward F

AU - Uribe, Liliana

AU - Marx, Stephen J.

AU - Onobrakpeya, Olufunmilayo

AU - Raisz, Lawrence G.

AU - Watts, Nelson B.

AU - Sharon, Michael

AU - Levine, Michael A.

PY - 2002/3/2

Y1 - 2002/3/2

N2 - Oncogenic osteomalacia, an acquired hypophosphataemic syndrome associated with mesenchymal tumours, is characterised by hypophosphataemia secondary to inappropriate phosphaturia, reduced concentrations of serum calcitriol, and defective bone mineralisation. Removal of these tumours results in complete reversal of these biochemical defects. However, because these tumours are small, slow-growing, and frequently situated in unusual anatomical sites, conventional imaging techniques often fail to detect them. Since mesenchymal tumours express somatostatin receptors, we postulated that somatostatin analogues would be able to detect these tumours. We did Indium-111 labeled pentetreotide imaging in seven patients with oncogenic osteomalacia. In five patients, we identified a mesenchymal tumour, and clinical improvement occurred after tumour resection. Our findings suggest that 111In-pentetreotide imaging effectively detects occult mesenchymal tumours and facilitates surgical treatment of oncogenic osteomalacia.

AB - Oncogenic osteomalacia, an acquired hypophosphataemic syndrome associated with mesenchymal tumours, is characterised by hypophosphataemia secondary to inappropriate phosphaturia, reduced concentrations of serum calcitriol, and defective bone mineralisation. Removal of these tumours results in complete reversal of these biochemical defects. However, because these tumours are small, slow-growing, and frequently situated in unusual anatomical sites, conventional imaging techniques often fail to detect them. Since mesenchymal tumours express somatostatin receptors, we postulated that somatostatin analogues would be able to detect these tumours. We did Indium-111 labeled pentetreotide imaging in seven patients with oncogenic osteomalacia. In five patients, we identified a mesenchymal tumour, and clinical improvement occurred after tumour resection. Our findings suggest that 111In-pentetreotide imaging effectively detects occult mesenchymal tumours and facilitates surgical treatment of oncogenic osteomalacia.

UR - http://www.scopus.com/inward/record.url?scp=0037006672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037006672&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(02)07846-7

DO - 10.1016/S0140-6736(02)07846-7

M3 - Article

C2 - 11888589

AN - SCOPUS:0037006672

VL - 359

SP - 761

EP - 763

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9308

ER -